Herbal Therapeutics for CIRS Biomarkers in Autism Spectrum Disorders: A Mechanistic and Molecular Approach for Neuroimmune Pathology in Pediatrics

Abstract

As the third article in a four-part series on pediatric neuroimmune disorders, this study evaluates evidence-based herbal therapeutics for biomarker modulation in Chronic Inflammatory Response Syndrome (CIRS). Building on Part 1 (CIRS diagnostic framework), Part 2 (infectious drivers such as Lyme disease and co-infections), and Part 4 (Autoimmune encephalopathy), Part 3 focuses on phytochemicals that target dysregulated markers, including TGF-β1, MMP-9, C4a, VEGF, VIP, and ADH. In a cohort of 1,722 children with treatment-resistant autism spectrum disorder (ASD) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)138,140, all meeting CIRS criteria via bedside diagnosis, targeted herbal interventions were introduced, with reported improvements including but not limited to cognition, language, behavior, respiratory, sleep, pain, and gastrointestinal function. Mechanistic pathways included modulation of NF-κB, SMAD2/3, and Nrf2, supporting reduction of inflammation and restoration of neurovascular integrity. Bedside diagnostic strategies, necessitated by laboratory constraints, were supported by control data (83 children 141,142). Outcomes suggest that herbal therapeutics may serve as viable and valuable adjuncts to the Shoemaker CIRS Protocol, offering improved tolerability and accessibility. This work underscores a systems biology approach to pediatric CIRS management and highlights integrative strategies that bridge conventional and botanical medicine 1, 3, 4,6, 50, 51, 139,141,142.

Key Biomarkers

Symptom Clusters